Mylan builds on its strong momentum by acquiring Abbott’s non-U.S. developed markets specialty and branded generics business. We are now a workforce of approximately 30,000 individuals personally dedicated to setting new standards in health care and providing the world’s 7 billion people access to high quality medicine. Together, we believe we can create better health for a better world, one person at a time.

The deal expands and further diversifies our business in our largest markets outside of the U.S., and clearly positions us for our next phase of growth. This highly complementary combination provides doctors and pharmacists with more choices and gives patients increased access to high quality medicine. It also opens up new channels for Mylan to introduce important products, such respiratory medications and biosimilars.

Diverse Product Portfolio

Mylan already offers one of the broadest portfolios in the industry, with more than 1,300 products across a range of therapeutic categories. The Abbott deal contributes an additional 100 medications, many of which are novel and/or hard to manufacture. The products include specialty, branded generic and over-the-counter (OTC) medicines in the following major therapeutic categories:

• Cardio/Metabolic
• Gastrointestinal
• Anti-infective/Respiratory
• Central Nervous System/Pain
• Women's and Men's Health

Geographic Expansion

The Abbott acquisition expands our geographic reach in our largest markets outside of the U.S. The transaction approximately doubles our revenues in Europe by strengthening our presence in Italy, the United Kingdom, Germany, France, Spain and Portugal, among others. It also more than doubles Mylan's revenues in Canada and Japan, and builds on our business in Australia and New Zealand. In addition, Mylan gains significant presence in the specialty and branded generics market in Central and Eastern Europe. The deal also adds two high quality facilities to our global manufacturing network, giving us even greater production capacity and flexibility.